A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma

Trial Profile

A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 19 May 2022 to 30 Apr 2022.
    • 12 Jun 2017 Planned primary completion date changed from 9 May 2019 to 20 Apr 2019.
    • 19 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top